Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $29,726.55 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Jeffrey Jerome Ludwig sold 9,437 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the transaction, the insider now owns 108,951 shares of the company’s stock, valued at $343,195.65. This trade represents a 7.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Puma Biotechnology Trading Down 5.4 %

Shares of NASDAQ:PBYI opened at $2.95 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The firm has a market capitalization of $144.81 million, a P/E ratio of 6.15 and a beta of 1.10. The business’s 50-day moving average is $2.99 and its 200 day moving average is $2.97. Puma Biotechnology, Inc. has a 1 year low of $2.22 and a 1 year high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.31 by $0.10. The business had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the previous year, the firm posted $0.12 earnings per share. On average, research analysts predict that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Institutional Trading of Puma Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. lifted its position in Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after purchasing an additional 246,264 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Puma Biotechnology by 1.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock valued at $5,715,000 after buying an additional 23,600 shares during the period. Great Point Partners LLC boosted its stake in shares of Puma Biotechnology by 10.6% in the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after buying an additional 142,916 shares during the last quarter. American Century Companies Inc. grew its holdings in Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after acquiring an additional 366,653 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Puma Biotechnology by 6.6% during the second quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock valued at $1,975,000 after acquiring an additional 37,684 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PBYI shares. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research report on Monday, December 23rd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.